Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment

Abstract

Digestive diseases comprise a diverse range of illnesses, which are prevalent worldwide and represent an important health issue. This is particularly relevant for the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) due to its close association with the obesity pandemic, contributing to the escalation of MASLD as the most common form of chronic liver disease, and the main cause of liver cancer.

References

[1] Unalp-Arida A, Ruhl CE. Burden of Digestive Diseases in the United States Population: Rates and Trends. Am J Gastroenterol. 2024; 120: 1987-97.

[2] GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1160-203.

[3] Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2020; 21: 5888.

[4] Eslam M, Sanyal AJ, George J ; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158: 1999-2014.e1.

[5] Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79: 1542-56.

[6] Cusi K, Younossi Z, Roden M. From NAFLD to MASLD: Promise and pitfalls of a new definition. J Hepatol. 2024; 81: e18-9.

[7] Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome? Metab Target Organ Damage. 2024; 4: 10.

[8] Sanal MG, Gish RG, Méndez-Sánchez N, Yu ML, Chan WK, Wei L, et al. NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease. Metab Target Organ Damage. 2024; 4: 45.

[9] Petrie E, Gray M, Bril F. Metabolic characteristics of patients with MetALD: Caveats of a new definition. Liver Int. 2024; 44: 2929-38.

[10] Lonardo A, Bril F, Caldwell SH, Eslam M, Fan JG, Gish RG, et al. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature. J Hepatol. 2024; 80: e192-4.

[11] Lonardo A, Zheng MH, Eslam M. MASLD vs. MAFLD. A narrative review. Explor Dig Dis. 2025; 4: 100586.

[12] Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025; 31: S32-50.

[13] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81: 492-542.

[14] Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol. 2023; 79: 1524-41.

[15] Cherubini A, Della Torre S, Pelusi S, Valenti L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol Med. 2024; 30: 1126-36.

[16] Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, et al. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 19: 61-71.e15.

[17] Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology. 2019; 157: 54-64.

[18] Mantovani A, Lonardo A, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers. Metabolism. 2024; 160: 156014.

[19] Bril F, Elbert A. Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern? Metabolism. 2025; 162: 156066.

[20] Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018; 155: 443-57.e17.

[21] Lonardo A, Stefan N, Mantovani A. Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. Trends Endocrinol Metab. 2025; 36: 610-3.

[22] Lonardo A. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review. Metab Target Organ Damage. 2024; 4: 16.

[23] Schnell O, Almandoz J, Anderson L, Barnard-Kelly K, Battelino T, Blüher M, et al. CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2025; 24: 187.

[24] Ahmed A, Cule M, Bell JD, Sattar N, Yaghootkar H. Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer. J Hepatol. 2024; 81: 921-9.

[25] Wang W, Sun P, Ren X, Lv T, Li M. The Effect of Nonalcoholic Fatty Liver Disease on Extrahepatic Cancers: Evidence From Population-Based Cohort and Mendelian Randomization. Health Sci Rep. 2025; 8: e70551.

[26] Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024; 73: 691-702.

[27] Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013; 48: 434-41.

[28] Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022; 18: 55-66.

[29] Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2019; 103: e1-13.

[30] Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021; 73: 833-42.

[31] Stern JH, Rutkowski JM, Scherer PE. Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab. 2016; 23: 770-84.

[32] Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology. 2020; 159: 849-63.

[33] Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024; 12: 1433857.

[34] Weiskirchen R, Lonardo A. PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology. J Transl Genet Genom. 2024; 8: 355-77.

[35] Sookoian S, Rotman Y, Valenti L. Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update. Clin Gastroenterol Hepatol. 2024; 22: 2177-87.e3.

[36] BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A. 2019; 116: 9521-6.

[37] Conde de la Rosa L, Garcia-Ruiz C, Vallejo C, Baulies A, Nuñez S, Monte MJ, et al. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. J Hepatol. 2021; 74: 1429-41.

[38] Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025; 82: 134-53.

[39] Gao Y, Lin J, Ye C, Guo S, Jiang C. Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease. Liver Res. 2023; 7: 165-76.

[40] Ku JL, Hsu JR, Li YT, Wu LL. Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review. J Gastroenterol Hepatol. 2025; 40: 33-40.

[41] Lai J, Luo L, Zhou T, Feng X, Ye J, Zhong B. Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. Biomolecules. 2023; 13: 1356.

[42] Marí M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006; 4: 185-98.

[43] Chen MM, Hale C, Stanislaus S, Xu J, Véniant MM. FGF21 acts as a negative regulator of bile acid synthesis. J Endocrinol. 2018; 237: 139-52.

[44] Segovia-Miranda F, Morales-Navarrete H, Kücken M, Moser V, Seifert S, Repnik U, et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat Med. 2019; 25: 1885-93.

[45] Murphy WA, Diehl AM, Loop MS, Fu D, Guy CD, Abdelmalek MF, et al. Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD. Hepatol Commun. 2024; 8: e0377.

[46] Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023; 20: 708-22.

[47] Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, et al. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016; 151: 1046-55.

[48] Arterburn DE, Olsen MK, Smith VA, Livingston EH, Van Scoyoc L, Yancy WS Jr, et al. Association between bariatric surgery and long-term survival. JAMA. 2015; 313: 62-70.

[49] Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA. 2021; 326: 2031-42.

[50] Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S ; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373: 2117-28.

[51] Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9: 653-62.

[52] Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121-30.

[53] Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al.; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021; 384: 1113-24.

[54] Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS ; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025; 392: 2089-99.

[55] Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025; 389: e083735.

[56] Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al.; SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024; 391: 299-310.

[57] Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al.; 1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024; 391: 311-9.

[58] Knezović E, Hefer M, Blažanović S, Petrović A, Tomičić V, Srb N, et al. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr Issues Mol Biol. 2025; 47: 154.

[59] Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al.; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024; 390: 497-509.

[60] Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023; 389: 998-1008.

[61] Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025; 392: 2413-24.

[62] Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al.; ELATIVE Study Investigators’ Group. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024; 390: 795-805.

[63] Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, et al.; RESPONSE Study Group. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024; 390: 783-94.

[64] Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al.; NATIVE Study Group. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021; 385: 1547-58.

[65] Gardin A, Remih K, Gonzales E, Andersson ER, Strnad P. Modern therapeutic approaches to liver-related disorders. J Hepatol. 2022; 76: 1392-409.

[66] Fabbrini E, Rady B, Koshkina A, Jeon JY, Ayyar VS, Gargano C, et al. Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD. N Engl J Med. 2024; 391: 475-6.

[67] Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, et al. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2023; 78: 684-92.

[68] Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, et al. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial. JAMA. 2024; 331: 920-9.

[69] Caballero F, Fernández A, De Lacy AM, Fernández-Checa JC, Caballería J, García-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009; 50: 789-96.

[70] Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012; 15: 665-74.

[71] Yun B, Park H, Lee J, Kim BK, Yoon JH. Statin use and liver-related prognosis among patients with MASLD. JHEP Rep. 2024; 7: 101313.

[72] Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies. Clin Invest Med. 2007; 30: 33-41.

[73] Nielsen DG, Andersen K, Nielsen AS, Nielsen F, Behrendt S, Bilberg R, et al. Comparison of self-reported alcohol consumption and ethyl glucuronide in hair in a sample of 60+ year-olds treated for DSM-5 alcohol use disorder. Addict Biol. 2022; 27:e13231.

[74] Ravelli MN, Schoeller DA. Traditional Self-Reported Dietary Instruments Are Prone to Inaccuracies and New Approaches Are Needed. Front Nutr. 2020; 7: 90.

[75] Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clin Gastroenterol Hepatol. 2024; 22: 1330-2.e4.

[76] Ochoa-Allemant P, Marrero JA, Serper M. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States. Hepatol Commun. 2023; 7: e0324.

[77] Ong C, Tang N, Gunalan S, Teng M, Koh B, Chee D, et al. Prevalence and longitudinal effects on mortality associated with spectrum of alcohol intake in steatotic liver disease: a United States population study. Hepatobiliary Surg Nutr. 2025; 14: 222-32.

[78] Schneider KM, Schneider CV. A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank. J Hepatol. 2024; 80: e58-60.

[79] Alcohol consumption in the United Kingdom (UK) - Statistics & Facts [Internet]. Statista; [cited 2025 Dec 17]. Available from: https://www.statista.com/topics/3281/alcohol-use-in-the-united-kingdom/#statisticChapter

[80] Alcohol use in the United States - Statistics & Facts [Internet]. Statista; [cited 2025 Dec 17]. Available from: https://www.statista.com/topics/2301/alcohol-and-health/

[81] Bridger Staatz C, Gutin I, Tilstra A, Gimeno L, Moltrecht B, Moreno-Agostino D, et al. Midlife health in Britain and the United States: a comparison of two nationally representative cohorts. Int J Epidemiol. 2024; 53: dyae127.

[82] Stockwell T, Donath S, Cooper-Stanbury M, Chikritzhs T, Catalano P, Mateo C. Under-reporting of alcohol consumption in household surveys: a comparison of quantity-frequency, graduated-frequency and recent recall. Addiction. 2004; 99: 1024-33.

[83] Stockwell T, Zhao J, Macdonald S. Who under-reports their alcohol consumption in telephone surveys and by how much? An application of the ‘yesterday method’ in a national Canadian substance use survey. Addiction. 2014; 109: 1657-66.

[84] Harris JC, Leggio L, Farokhnia M. Blood Biomarkers of Alcohol Use: A Scoping Review. Curr Addict Rep. 2021; 8: 500- 8.

[85] Kane JC, Chirayil P, Pawar R, Inoue S, Hofer T, McDonell M, et al. Measuring alcohol consumption with biomarkers in intervention studies: A scoping review. Alcohol Clin Exp Res (Hoboken). 2025; 49: 1843-54.

[86] Grüner Nielsen D, Andersen K, Søgaard Nielsen A, Juhl C, Mellentin A. Consistency between self-reported alcohol consumption and biological markers among patients with alcohol use disorder - A systematic review. Neurosci Biobehav Rev. 2021; 124: 370-85.

[87] Marek GW, Malhi H. MetALD: Does it require a different therapeutic option? Hepatology. 2024; 80: 1424-40.

[88] Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009; 360: 2758-69.

[89] Yamazaki T, Schnabl B. Acute alcohol-associated hepatitis: Latest findings in non-invasive biomarkers and treatment. Liver Int. 2025; 45: e15608.

[90] Ji H, Cheng S, Heart-Liver Axis Research Collaboration. Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters. J Hepatol. 2024; 80: e68-9.

[91] Wagnerberger S, Fiederlein L, Kanuri G, Stahl C, Millonig G, Mueller S, et al. Sex-specific differences in the development of acute alcohol-induced liver steatosis in mice. Alcohol Alcohol. 2013; 48: 648-56.

[92] Yin M, Ikejima K, Wheeler MD, Bradford BU, Seabra V, Forman DT, et al. Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model. Hepatology. 2000; 31: 117-23.

[93] Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990; 322: 95-9.

[94] Ikejima K, Enomoto N, Iimuro Y, Ikejima A, Fang D, Xu J, et al. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol. 1998; 274: G669-76.

[95] van Kleef LA, de Knegt RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. Hepatology. 2023; 77: 942-8.

[96] Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019; 17: 1625-33.e1.

[97] Idalsoaga F, Kulkarni AV, Mousa OY, Arrese M, Arab JP. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Front Med (Lausanne). 2020; 7: 448.

[98] Malnick SDH, Alin P, Somin M, Neuman MG. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. Int J Mol Sci. 2022; 23: 16226.

[99] Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight. 2017; 2:e95354.

[100] Acierno C, Barletta F, Caturano A, Nevola R, Sasso FC, Adinolfi LE, et al. Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights. Nutrients. 2025; 17: 2229.

[101] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017; 14: 397-411.

[102] Benedé-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024; 16: 2331460.

[103] Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015; 148: 30-6.

[104] Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology. 1995; 108: 218-24.

[105] Brandt A, Csarmann K, Hernández-Arriaga A, Baumann A, Staltner R, Halilbasic E, et al. Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction. J Nutr Biochem. 2024; 123: 109495.

[106] Burger K, Jung F, Staufer K, Ladurner R, Trauner M, Baumann A, et al. MASLD is related to impaired alcohol dehydrogenase (ADH) activity and elevated blood ethanol levels: Role of TNFα and JNK. Redox Biol. 2024; 71: 103121.

[107] Engstler AJ, Aumiller T, Degen C, Dürr M, Weiss E, Maier IB, et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut. 2016; 65: 1564-71.

[108] Ahmed Selim N, Wojtovich AP. Mitochondrial membrane potential and compartmentalized signaling: Calcium, ROS, and beyond. Redox Biol. 2025; 86: 103859.

[109] Xu X, Pang Y, Fan X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025; 10: 190.

[110] Randhawa J, Pålsson-McDermott EM. Beyond energy: how TCA cycle-derived metabolites regulate gene expression and inflammation in the nucleus. J Inflamm (Lond). 2025; 22: 39.

[111] Quintana-Cabrera R, Scorrano L. Determinants and outcomes of mitochondrial dynamics. Mol Cell. 2023; 83: 857-76.

[112] Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol. 2005; 42: 928-40.

[113] Torres S, Hardesty J, Barrios M, Garcia-Ruiz C, Fernandez-Checa JC, Singal AK. Mitochondria and Alcohol-Associated Liver Disease: Pathogenic Role and Target for Therapy. Semin Liver Dis. 2025; 45: 180-94.

[114] Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res. 2020; 61: 470-9.

[115] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018; 391: 1301-14.

[116] Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150: 835-53.

[117] Lu Y, George J. Interaction between fatty acid oxidation and ethanol metabolism in liver. Am J Physiol Gastrointest Liver Physiol. 2024; 326: G483-94.

[118] Sleigh A, Raymond-Barker P, Thackray K, Porter D, Hatunic M, Vottero A, et al. Mitochondrial dysfunction in patients with primary congenital insulin resistance. J Clin Invest. 2011; 121: 2457-61.

[119] Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003; 38: 999-1007.

[120] Abu-Elheiga L, Brinkley WR, Zhong L, Chirala SS, Woldegiorgis G, Wakil SJ. The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci U S A. 2000; 97: 1444-9.

[121] McGarry JD, Mannaerts GP, Foster DW. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest. 1977; 60: 265-70.

[122] Rawson RB, DeBose-Boyd R, Goldstein JL, Brown MS. Failure to cleave sterol regulatory element-binding proteins (SREBPs) causes cholesterol auxotrophy in Chinese hamster ovary cells with genetic absence of SREBP cleavage-activating protein. J Biol Chem. 1999; 274: 28549-56.

[123] Orellana-Gavaldà JM, Herrero L, Malandrino MI, Pañeda A, Sol Rodríguez-Peña M, Petry H, et al. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. Hepatology. 2011; 53: 821-32.

[124] Hwang KA, Hwang YJ, Kim GR, Choe JS. Extracts from Aralia elata (Miq) Seem alleviate hepatosteatosis via improving hepatic insulin sensitivity. BMC Complement Altern Med. 2015; 15: 347.

[125] García-Ruiz C, Fernández-Checa JC. Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease. Hepatol Commun. 2018; 2: 1425-39.

[126] Win S, Than TA, Kaplowitz N, Wong N, Arya A, Win ZT, et al. The central role of mitochondrial metabolism in hepatic steatosis. Explor Dig Dis. 2024; 3: 42-68.

[127] Fàbrega L, Fernández-Checa JC, Conde de la Rosa L, Garcia-Ruiz C. Impact of mitochondrial lipid alterations on liver disease mechanisms and progression. Explor Dig Dis. 2024; 3: 382-413.

[128] Caron KM, Soo SC, Wetsel WC, Stocco DM, Clark BJ, Parker KL. Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci U S A. 1997; 94: 11540-5.

[129] Ramírez S, Haddad-Tóvolli R, Radosevic M, Toledo M, Pané A, Alcolea D, et al. Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders. Cell Metab. 2022; 34: 269-84.e9.

[130] Fucho R, Solsona-Vilarrasa E, Torres S, Nuñez S, Insausti-Urkia N, Edo A, et al. Zonal expression of StARD1 and oxidative stress in alcoholic-related liver disease. J Lipid Res. 2023; 64: 100413.

[131] Fernandez A, Matias N, Fucho R, Ribas V, Von Montfort C, Nuño N, et al. ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol. 2013; 59: 805-13.

[132] Torres S, Matías N, Baulies A, Nuñez S, Alarcon-Vila C, Martinez L, et al. Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease. Redox Biol. 2017; 11: 60-72.

[133] Solsona-Vilarrasa E, Fucho R, Torres S, Nuñez S, Nuño-Lámbarri N, Enrich C, et al. Cholesterol enrichment in liver mitochondria impairs oxidative phosphorylation and disrupts the assembly of respiratory supercomplexes. Redox Biol. 2019; 24: 101214.

[134] Bosch M, Marí M, Herms A, Fernández A, Fajardo A, Kassan A, et al. Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. Curr Biol. 2011; 21: 681-6.

[135] Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basañez G, et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008; 68: 5246-56.

[136] Torres S, Fernandez-Checa JC, Garcia-Ruiz C. Hypoxia signaling and cholesterol/steroidogenic acute regulatory protein 1 axis: interplay and role in alcohol and non-alcohol-related liver diseases. Explor Dig Dis. 2022; 1: 170-86.

[137] Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018; 69: 396-405.

[138] Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell. 2007; 131: 476-91.

[139] Wredenberg A, Freyer C, Sandström ME, Katz A, Wibom R, Westerblad H, et al. Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance. Biochem Biophys Res Commun. 2006; 350: 202-7.

[140] Vernochet C, Mourier A, Bezy O, Macotela Y, Boucher J, Rardin MJ, et al. Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab. 2012; 16: 765-76.

[141] Han D, Ybanez MD, Johnson HS, McDonald JN, Mesropyan L, Sancheti H, et al. Dynamic adaptation of liver mitochondria to chronic alcohol feeding in mice: biogenesis, remodeling, and functional alterations. J Biol Chem. 2012; 287: 42165-79.

[142] Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013; 3: 1191-212.

[143] Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017; 65: 350-62.

[144] Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012; 55: 267-76.

[145] Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016; 7: 22-39.

[146] Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, et al. Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. PLoS One. 2016; 11:e0147210.

[147] Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control T_H17 and T_reg cell differentiation. Nature. 2019; 576: 143-8.

[148] Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 2016; 24: 41-50.

[149] Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013; 62: 531-9.

[150] Meng L, Lu F, Zhang B, Ma Y, Gao J. Taming fatty liver: can taurine combat metabolic dysfunction in MASLD? Cell Commun Signal. 2025; 23: 439.

[151] Heinken A, Hertel J, Thiele I. Metabolic modelling reveals broad changes in gut microbial metabolism in inflammatory bowel disease patients with dysbiosis. npj Syst Biol Appl. 2021; 7: 19.

[152] Ajouz H, Mukherji D, Shamseddine A. Secondary bile acids: an underrecognized cause of colon cancer. World J Surg Oncol. 2014; 12: 164.

[153] Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020; 17: 223-37.

[154] Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol. 2010; 3: 349-57.

[155] Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2015; 41: 54-64.

[156] Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol. 2013; 11: 1232-9.

[157] Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M, et al. Cholestatic liver diseases: An era of emerging therapies. World J Clin Cases. 2019; 7: 1571-81.

[158] norUrsodeoxycholic Acid vs Placebo in PSC [Internet]. National Library of Medicine; [cited 2025 Sep 16]. Available from: https://clinicaltrials.gov/study/NCT03872921

[159] Conde de la Rosa L, Fàbrega L, Torres S, Nuñez S, Ribas V, Segalés P, et al. Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity. Hepatology. 2025; 82: 293-307.

[160] Sutton H, Soko RJ, Kamath BM. IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon? Hepatology. 2025; 82: 985-95.

[161] Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011; 60: 463-72.

[162] Huang TC, Kou T, Kuo CJ, Chiu CH, Chen TD, Chen CM, et al. Enteric opportunistic infections in patients with inflammatory bowel disease receiving biologic therapies: a retrospective cohort study. Gut Pathog. 2025;[Epub ahead of print].

[163] Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res. 2005; 589: 47-65.

[164] Yang J, Tang X, Liang Z, Chen M, Sun L. Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions. Clin Mol Hepatol. 2023; 29: 465-81.

[165] Li T, Apte U. Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. Adv Pharmacol. 2015; 74: 263-302.

[166] Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023; 79: 552-66.

[167] Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E. Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments. Cells. 2024; 13: 1650.

[168] Zerem E, Kunosic S, Kurtcehajic A, Zerem D, Zerem O. Bile acids in metabolic dysfunction-associated steatotic liver disease. World J Hepatol. 2025; 17: 108606.

[169] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385: 956-65.

[170] Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017; 66: 1154-64.

[171] Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019; 394: 869-81.

[172] Jaeschke H, Ramachandran A. Acetaminophen Hepatotoxicity: Paradigm for Understanding Mechanisms of Drug-Induced Liver Injury. Annu Rev Pathol. 2024; 19: 453-78.

[173] Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000; 290: 1717-21.

[174] Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008; 451: 1069-75.

[175] Mizushima N. A brief history of autophagy from cell biology to physiology and disease. Nat Cell Biol. 2018; 20: 521-7.

[176] Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011; 147: 728-41.

[177] Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011; 12: 9-14.

[178] Chino H, Mizushima N. ER-Phagy: Quality Control and Turnover of Endoplasmic Reticulum. Trends Cell Biol. 2020; 30: 384-98.

[179] Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal. 2014; 20: 460-73.

[180] Schuck S. Microautophagy - distinct molecular mechanisms handle cargoes of many sizes. J Cell Sci. 2020; 133: jcs246322.

[181] Marzella L, Ahlberg J, Glaumann H. Autophagy, heterophagy, microautophagy and crinophagy as the means for intracellular degradation. Virchows Arch B Cell Pathol Incl Mol Pathol. 1981; 36: 219-34.

[182] Cuervo AM, Dice JF. Age-related decline in chaperone-mediated autophagy. J Biol Chem. 2000; 275: 31505-13.

[183] Arias E, Cuervo AM. Chaperone-mediated autophagy in protein quality control. Curr Opin Cell Biol. 2011; 23: 184-9.

[184] Tekirdag K, Cuervo AM. Chaperone-mediated autophagy and endosomal microautophagy: Joint by a chaperone. J Biol Chem. 2018; 293: 5414-24.

[185] Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol. 2018; 19: 365-81.

[186] Wang L, Klionsky DJ, Shen HM. The emerging mechanisms and functions of microautophagy. Nat Rev Mol Cell Biol. 2023; 24: 186-203.

[187] Ni HM, McGill MR, Chao X, Du K, Williams JA, Xie Y, et al. Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice. J Hepatol. 2016; 65: 354-62.

[188] Ni HM, Bockus A, Boggess N, Jaeschke H, Ding WX. Activation of autophagy protects against acetaminophen-induced hepatotoxicity. Hepatology. 2012; 55: 222-32.

[189] Nguyen NT, Akakpo JY, Weemhoff JL, Ramachandran A, Ding WX, Jaeschke H. Impaired protein adduct removal following repeat administration of subtoxic doses of acetaminophen enhances liver injury in fed mice. Arch Toxicol. 2021; 95: 1463-73.

[190] Ni HM, Boggess N, McGill MR, Lebofsky M, Borude P, Apte U, et al. Liver-specific loss of Atg5 causes persistent activation of Nrf2 and protects against acetaminophen-induced liver injury. Toxicol Sci. 2012; 127: 438-50.

[191] Sun Y, Li TY, Song L, Zhang C, Li J, Lin ZZ, et al. Liver-specific deficiency of unc-51 like kinase 1 and 2 protects mice from acetaminophen-induced liver injury. Hepatology. 2018; 67: 2397-413.

[192] Ramachandran A, Jaeschke H. A mitochondrial journey through acetaminophen hepatotoxicity. Food Chem Toxicol. 2020; 140: 111282.

[193] Wang H, Ni HM, Chao X, Ma X, Rodriguez YA, Chavan H, et al. Double deletion of PINK1 and Parkin impairs hepatic mitophagy and exacerbates acetaminophen-induced liver injury in mice. Redox Biol. 2019; 22: 101148.

[194] Fang Z, Xu Y, Liu G, Shao Q, Niu X, Tai W, et al. Narirutin activates TFEB (transcription factor EB) to protect against Acetaminophen-induced liver injury by targeting PPP3/calcineurin. Autophagy. 2023; 19: 2240-56.

[195] Chao X, Niu M, Wang S, Ma X, Yang X, Sun H, et al. High-throughput screening of novel TFEB agonists in protecting against acetaminophen-induced liver injury in mice. Acta Pharm Sin B. 2024; 14: 190-206.

[196] Xu L, Wang H. A dual role of inflammation in acetaminophen-induced liver injury. Liver Res. 2023; 7: 9-15.

[197] Nguyen K, Ding WX, Ni HM. Multimodal decoding of human liver regeneration uncovers novel ANXA2⁺ migratory hepatocytes for wound healing. eGastroenterology. 2025; 3: e100205.

[198] Liu R, Cui J, Sun Y, Xu W, Wang Z, Wu M, et al. Autophagy deficiency promotes M1 macrophage polarization to exacerbate acute liver injury via ATG5 repression during aging. Cell Death Discov. 2021; 7: 397.

[199] Ilyas G, Cingolani F, Zhao E, Tanaka K, Czaja MJ. Decreased Macrophage Autophagy Promotes Liver Injury and Inflammation from Alcohol. Alcohol Clin Exp Res. 2019; 43: 1403-13.

[200] Zhan X, Bai Y, Zhu Q, Gao Y, Li F, Bu Q, et al. Macrophage ATG16L1 promotes liver regeneration after partial hepatectomy. JHEP Rep. 2025; 7: 101330.

[201] Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, Verdonk RC, Boermeester MA, et al. Acute pancreatitis. Lancet. 2020; 396: 726-34.

[202] Mederos MA, Reber HA, Girgis MD. Acute Pancreatitis: A Review. JAMA. 2021; 325: 382-90.

[203] Ding WX, Ma X, Kim S, Wang S, Ni HM. Recent insights about autophagy in pancreatitis. eGastroenterology. 2024; 2: e100057.

[204] Mareninova OA, Sendler M, Malla SR, Yakubov I, French SW, Tokhtaeva E, et al. Lysosome associated membrane proteins maintain pancreatic acinar cell homeostasis: LAMP-2 deficient mice develop pancreatitis. Cell Mol Gastroenterol Hepatol. 2015; 1: 678-94.

[205] Antonucci L, Fagman JB, Kim JY, Todoric J, Gukovsky I, Mackey M, et al. Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress. Proc Natl Acad Sci U S A. 2015; 112: E6166-74.

[206] Mainz L, Sarhan MAFE, Roth S, Sauer U, Kalogirou C, Eckstein M, et al. Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice. Autophagy. 2022; 18: 2880-93.

[207] Wang S, Ni HM, Chao X, Ma X, Kolodecik T, De Lisle R, et al. Critical Role of TFEB-Mediated Lysosomal Biogenesis in Alcohol-Induced Pancreatitis in Mice and Humans. Cell Mol Gastroenterol Hepatol. 2020; 10: 59-81.

[208] Mareninova OA, Gretler SR, Lee GE, Pimienta M, Qin Y, Elperin JM, et al. Ethanol inhibits pancreatic acinar cell autophagy through upregulation of ATG4B, mediating pathological responses of alcoholic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2023; 325: G265-78.

[209] Morishita H, Zhao YG, Tamura N, Nishimura T, Kanda Y, Sakamaki Y, et al. A critical role of VMP1 in lipoprotein secretion. Elife. 2019; 8: e48834.

[210] Morita K, Hama Y, Mizushima N. TMEM41B functions with VMP1 in autophagosome formation. Autophagy. 2019; 15: 922-3.

[211] Zhang T, Li YE, Yuan Y, Du X, Wang Y, Dong X, et al. TMEM41B and VMP1 are phospholipid scramblases. Autophagy. 2021; 17: 2048-50.

[212] Chen A, Ding WX, Ni HM. Scramblases as Regulators of Autophagy and Lipid Homeostasis: Implications for NAFLD. Autophagy Rep. 2022; 1: 143-60.

[213] Jiang X, Fulte S, Deng F, Chen S, Xie Y, Chao X, et al. Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis. J Hepatol. 2022; 77: 619-31.

[214] Vaccaro MI, Grasso D, Ropolo A, Iovanna JL, Cerquetti MC. VMP1 expression correlates with acinar cell cytoplasmic vacuolization in arginine-induced acute pancreatitis. Pancreatology. 2003; 3: 69-74.

[215] Wang S, Chao X, Jiang X, Wang T, Rodriguez Y, Yang L, et al. Loss of acinar cell VMP1 triggers spontaneous pancreatitis in mice. Autophagy. 2022; 18: 1572-82.

[216] Wang S, Ni HM, Chao X, Wang H, Bridges B, Kumer S, et al. Impaired TFEB-mediated lysosomal biogenesis promotes the development of pancreatitis in mice and is associated with human pancreatitis. Autophagy. 2019; 15: 1954-69.

[217] Wang Q, Yu J, Gao W, Sun Y, Liu X, Lv Z, et al. The lncRNA TCONS_00021785/miR-21-5p/Trim33 axis regulates VMP1-mediated zymophagy, reduces the activation of trypsinogen, and promotes acinar cell recovery. Cell Death Discov. 2022; 8: 65.

[218] Biczo G, Vegh ET, Shalbueva N, Mareninova OA, Elperin J, Lotshaw E, et al. Mitochondrial Dysfunction, Through Impaired Autophagy, Leads to Endoplasmic Reticulum Stress, Deregulated Lipid Metabolism, and Pancreatitis in Animal Models. Gastroenterology. 2018; 154: 689-703.

[219] Ding WX, Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem. 2012; 393: 547-64.

[220] Ni HM, Williams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2015; 4: 6-13.

[221] Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken). 2008; 291: 684-92.

[222] Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016; 61: 1356-64.

[223] Shipovskaya AA, Dudanova OP. Intrahepatic cholestasis in nonalcoholic fatty liver disease. Ter Arkh. 2018; 90: 69-74.

[224] Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017; 46: 85-95.

[225] Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel). 2021; 10: 174.

[226] Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int. 2021; 15: 21-35.

[227] Miyao M, Kotani H, Ishida T, Kawai C, Manabe S, Abiru H, et al. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression. Lab Invest. 2015; 95: 1130-44.

[228] Geng Y, Arroyave-Ospina JC, Buist-Homan M, Plantinga J, Olinga P, Reijngoud DJ, et al. Differential effects of oleate on vascular endothelial and liver sinusoidal endothelial cells reveal its toxic features in vitro. J Nutr Biochem. 2023; 114: 109255.

[229] Pedroza-Diaz J, Arroyave-Ospina JC, Serna Salas S, Moshage H. Modulation of Oxidative Stress-Induced Senescence during Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel). 2022; 11: 975.

[230] Guo H, Diao N, Yuan R, Chen K, Geng S, Li M, et al. Subclinical-Dose Endotoxin Sustains Low-Grade Inflammation and Exacerbates Steatohepatitis in High-Fat Diet-Fed Mice. J Immunol. 2016; 196: 2300-8.

[231] Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997; 94: 2557-62.

[232] Ogawa Y, Imajo K, Honda Y, Kessoku T, Tomeno W, Kato S, et al. Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. Sci Rep. 2018; 8: 11365.

[233] Arroyave-Ospina JC, Martínez M, Buist-Homan M, Palasantzas V, Arrese M, Moshage H. Coffee Compounds Protection Against Lipotoxicity Is Associated with Lipid Droplet Formation and Antioxidant Response in Primary Rat Hepatocytes. Antioxidants (Basel). 2025; 14: 175.

[234] Martínez L, Torres S, Baulies A, Alarcón-Vila C, Elena M, Fabriàs G, et al. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis. Oncotarget. 2015; 6: 41479-96.

[235] Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016; 15: 249-74.

[236] Ajith TA. Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2018; 45: 413-21.

[237] Musso G, Cassader M, Paschetta E, Gambino R. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology. 2018; 155: 282-302.e8.

[238] Han J, Kaufman RJ. The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res. 2016; 57: 1329-38.

[239] Lee JN, Ye J. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. J Biol Chem. 2004; 279: 45257-65.

[240] Colgan SM, Tang D, Werstuck GH, Austin RC. Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int J Biochem Cell Biol. 2007; 39: 1843-51.

[241] Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab. 2010; 12 Suppl 2: 83-92.

[242] Zhou H, Liu R. ER stress and hepatic lipid metabolism. Front Genet. 2014; 5: 112.

[243] Huang Y, Zhao C, Kong Y, Tan P, Liu S, Liu Y, et al. Elucidation of the mechanism of NEFA-induced PERK-eIF2α signaling pathway regulation of lipid metabolism in bovine hepatocytes. J Steroid Biochem Mol Biol. 2021; 211: 105893.

[244] Fang D, Wan Y, Shen W, Cao J, Sun Z, Yu H, et al. Endoplasmic reticulum stress leads to lipid accumulation through upregulation of SREBP-1c in normal hepatic and hepatoma cells. Mol Cell Biochem. 2013; 381: 127-37.

[245] Xiao G, Zhang T, Yu S, Lee S, Calabuig-Navarro V, Yamauchi J, et al. ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice. J Biol Chem. 2013; 288: 25350-61.

[246] Ye J, Rawson RB, Komuro R, Chen X, Davé UP, Prywes R, et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell. 2000; 6: 1355-64.

[247] Ghemrawi R, Battaglia-Hsu S, Arnold C. Endoplasmic Reticulum Stress in Metabolic Disorders. Cells. 2018; 7: 63.

[248] Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE, et al. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis. 2025; 400: 119053.

[249] Shojaie L, Iorga A, Dara L. Cell Death in Liver Diseases: A Review. Int J Mol Sci. 2020; 21: 9682.

[250] Zhao J, Hu Y, Peng J. Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy. Cell Mol Biol Lett. 2021; 26: 17.

[251] Angeli JPF, Shah R, Pratt DA, Conrad M. Ferroptosis Inhibition: Mechanisms and Opportunities. Trends Pharmacol Sci. 2017; 38: 489-98.

[252] Conrad M, Friedmann Angeli JP. Glutathione peroxidase 4 (Gpx4) and ferroptosis: what’s so special about it? Mol Cell Oncol. 2015; 2:e995047.

[253] Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014; 16: 1180-91.

[254] Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med. 2019; 133: 130-43.

[255] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149: 1060-72.

[256] Tirosh O, Sen CK, Roy S, Packer L. Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death. Neuroscience. 2000; 97: 531-41.

[257] Kim KM, Cho SS, Ki SH. Emerging roles of ferroptosis in liver pathophysiology. Arch Pharm Res. 2020; 43: 985-96.

[258] Tsurusaki S, Tsuchiya Y, Koumura T, Nakasone M, Sakamoto T, Matsuoka M, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019; 10: 449.

[259] Qi J, Kim JW, Zhou Z, Lim CW, Kim B. Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice. Am J Pathol. 2020; 190: 68-81.

[260] Carlson BA, Tobe R, Yefremova E, Tsuji PA, Hoffmann VJ, Schweizer U, et al. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration. Redox Biol. 2016; 9: 22-31.

[261] Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003; 144: 5159-65.

[262] Homma T, Kobayashi S, Conrad M, Konno H, Yokoyama C, Fujii J. Nitric oxide protects against ferroptosis by aborting the lipid peroxidation chain reaction. Nitric Oxide. 2021; 115: 34-43.

[263] Mikulska-Ruminska K, Anthonymuthu TS, Levkina A, Shrivastava IH, Kapralov AA, Bayır H, et al. NO^● Represses the Oxygenation of Arachidonoyl PE by 15LOX/PEBP1: Mechanism and Role in Ferroptosis. Int J Mol Sci. 2021; 22: 5253.

[264] Abu-Halaka D, Shpaizer A, Zeigerman H, Kanner J, Tirosh O. DMF-Activated Nrf2 Ameliorates Palmitic Acid Toxicity While Potentiates Ferroptosis Mediated Cell Death: Protective Role of the NO-Donor S-Nitroso-N-Acetylcysteine. Antioxidants (Basel). 2023; 12: 512.

[265] Tirosh O, Artan A, Aharoni-Simon M, Ramadori G, Madar Z. Impaired liver glucose production in a murine model of steatosis and endotoxemia: protection by inducible nitric oxide synthase. Antioxid Redox Signal. 2010; 13: 13-26.

[266] Martínez-Clemente M, Ferré N, Titos E, Horrillo R, González-Périz A, Morán-Salvador E, et al. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology. 2010; 52: 1980-91.

[267] Shah R, Shchepinov MS, Pratt DA. Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. ACS Cent Sci. 2018; 4: 387-96.

[268] Snodgrass RG, Brüne B. Regulation and Functions of 15-Lipoxygenases in Human Macrophages. Front Pharmacol. 2019; 10: 719.

[269] Anavi S, Tirosh O. iNOS as a metabolic enzyme under stress conditions. Free Radic Biol Med. 2020; 146: 16-35.

[270] Nicolay JP, Müller-Decker K, Schroeder A, Brechmann M, Möbs M, Géraud C, et al. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB. Blood. 2016; 128: 805-15.

[271] Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, et al. Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL. Blood. 2021; 138: 871-84.

[272] Qi D, Chen P, Bao H, Zhang L, Sun K, Song S, et al. Dimethyl fumarate protects against hepatic ischemia-reperfusion injury by alleviating ferroptosis via the NRF2/SLC7A11/HO-1 axis. Cell Cycle. 2023; 22: 818-28.

[273] Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019; 23: 101107.

[274] Chang LC, Chiang SK, Chen SE, Yu YL, Chou RH, Chang WC. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett. 2018; 416: 124-37.

[275] Kwon MY, Park E, Lee SJ, Chung SW. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget. 2015; 6: 24393-403.

[276] Sui M, Jiang X, Chen J, Yang H, Zhu Y. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed Pharmacother. 2018; 106: 125-33.

[277] Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. 2025; 406: 731-78.

[278] Malhi H, Brown RS Jr, Lim JK, Reau N, Tapper EB, Wong CC, et al. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology. 2023; 78: 1680-1.

[279] Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022; 76: 681-93.

[280] Pascale A, Rosmorduc O, Duclos-Vallée JC. New epidemiologic trends in cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2023; 47: 102223.

[281] Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen H, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022; 76: 1109-21.

[282] Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al.; ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34: 127-40.

[283] Kahla JA, Siegel DA, Dai S, Lupo PJ, Foster JH, Scheurer ME, et al. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer. 2022; 69: e29763.

[284] Roehrig A, Hirsch TZ, Pire A, Morcrette G, Gupta B, Marcaillou C, et al. Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma. Nat Commun. 2024; 15: 3031.

[285] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82: 315-74.

[286] Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78: 1922-65.

[287] Rodgers SK, Fetzer DT, Seow JH, McGillen K, Burrowes DP, Fung C, et al. Optimizing US for HCC surveillance. Abdom Radiol (NY). 2025; 50: 2453-63.

[288] Nartey YA, Yang JD, Zemla TJ, Ayawin J, Asibey SO, El-Kassas M, et al. GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients. Cancer Res Commun. 2024; 4: 2653-9.

[289] Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, Toyoda H. Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. Br J Cancer. 2022; 127: 1263-9.

[290] Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020; 73: 1368-78.

[291] European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023; 79: 181-208.

[292] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. J Hepatol. 2025; 83: 211-38.

[293] Vogel A, Ducreux M ; ESMO Guidelines Committee. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025; 10: 104003.

[294] Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024; 35: 448-57.

[295] Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025; 83: 899-908.

[296] Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, et al. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial. Hepatology. 2025;[Epub ahead of print].

[297] Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al.; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24: 1399-410.

[298] Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma. ESMO Open. 2025; 10: 105065.

[299] Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23: 995-1008.

[300] Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024; 9: 310-22.

[301] Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, et al.; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025; 405: 216-32.

[302] Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023; 402: 1835-47.

[303] Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022; 1: EVIDoa2200015.

[304] Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al.; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401: 1853-65.

[305] Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat Commun. 2022; 13: 4594.

[306] Ye J, Lin Y, Liao Z, Gao X, Lu C, Lu L, et al. Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma. NPJ Precis Oncol. 2024; 8: 262.

[307] Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, et al. TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023; 79: 126-40.

[308] Cui H, Banerjee S, Xie N, Hussain M, Jaiswal A, Liu H, et al. TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity. Nat Commun. 2025; 16: 1761.

[309] Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592: 450-6.

[310] Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022; 71: 2093-106.

[311] Cappuyns S, Piqué-Gili M, Esteban-Fabró R, Philips G, Balaseviciute U, Pinyol R, et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J Hepatol. 2025; 82: 1036-49.

[312] Zuyin L, Zhao L, Qian C, Changkun Z, Delin M, Jialing H, et al. Single-Cell and Spatial Transcriptomics Delineate the Microstructure and Immune Landscape of Intrahepatic Cholangiocarcinoma in the Leading-Edge Area. Adv Sci (Weinh). 2025; 12: e2412740.

[313] Dong ZR, Zhang MY, Qu LX, Zou J, Yang YH, Ma YL, et al. Spatial resolved transcriptomics reveals distinct cross-talk between cancer cells and tumor-associated macrophages in intrahepatic cholangiocarcinoma. Biomark Res. 2024; 12: 100.

[314] Zhong YJ, Luo XM, Liu F, He ZQ, Yang SQ, Ma WJ, et al. Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma. J Transl Med. 2024; 22: 422.

[315] Golino JL, Bian J, Wang X, Fu J, Zhu XB, Yeo J, et al. Single-cell RNA sequencing reveals cancer stem-like cells and dynamics in tumor microenvironment during cholangiocarcinoma progression. Front Cell Dev Biol. 2023; 11: 1250215.

[316] Jiang Y, Yu Y, Pan Z, Glandorff C, Sun M. Ferroptosis: a new hunter of hepatocellular carcinoma. Cell Death Discov. 2024; 10: 136.

[317] Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016; 22: 851-60.

[318] Yang M, Li M, Lyu Z, Yang Z. Implication of Ferroptosis in Cholangiocarcinoma: A Potential Future Target? Cancer Manag Res. 2023; 15: 335-42.

[319] Ko S, Kim M, Molina L, Sirica AE, Monga SP. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. Adv Cancer Res. 2022; 156: 283-317.

[320] Song X, Xu H, Wang P, Wang J, Affo S, Wang H, et al. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. J Hepatol. 2021; 75: 888-99.

[321] Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015; 261: 947-55.

[322] Choi WJ, Williams PJ, Claasen MPAW, Ivanics T, Englesakis M, Gallinger S, et al. Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection. Ann Surg Oncol. 2022; 29: 4337-53.

[323] Malik AK, Geh D, Jeffry Evans TR, Chow PKH, Mann DA, White SA. Improving surgical treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2025;[Epub ahead of print].

[324] Zheng J, Cai J, Li H, Zeng K, He L, Fu H, et al. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review. Cell Physiol Biochem. 2017; 44: 967-81.

[325] Liu D, Czigany Z, Heij LR, Bouwense SAW, van Dam R, Lang SA, et al. The Value of Platelet-to-Lymphocyte Ratio as a Prognostic Marker in Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022; 14: 438.

[326] Yopp AC, Majella Doyle MB. Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2024; 33: xv-i.

[327] Zhao LM, Shi AD, Yang Y, Liu ZL, Hu XQ, Shu LZ, et al. Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma. Front Oncol. 2023; 13: 1140103.

[328] Xiao H, Ji J, Li S, Lai J, Wei G, Wu J, et al. Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial. JAMA Oncol. 2025; 11: 1021-9.

[329] Rothacker DL, Kanerva RL, Wyder WE, Alden CL, Maurer JK. Effects of variation of necropsy time and fasting on liver weights and liver components in rats. Toxicol Pathol. 1988; 16: 22-6.

[330] Dantzer C, Dif L, Vaché J, Basbous S, Billottet C, Moreau V. Specific features of β-catenin-mutated hepatocellular carcinomas. Br J Cancer. 2024; 131: 1871-80.

[331] Li XJ, Qu JR, Zhang YH, Liu RP. The dual function of cGAS-STING signaling axis in liver diseases. Acta Pharmacol Sin. 2024; 45: 1115-29.

[332] Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al.; FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023; 388: 228-39.

[333] Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, et al. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024; 9: 103488.

[334] Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Soldà C, et al. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. Ther Adv Med Oncol. 2023; 15: 17588359231171574.

[335] Smolenschi C, Blanc JF, Lancry A, Klajer E, Debaillon-Vesque A, Vantelon JM, et al. Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers. Eur J Cancer. 2025; 222: 115432.

[336] Han SY. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs. Pharmaceuticals (Basel). 2021; 14: 632.

[337] Yeh SH, Li CL, Lin YY, Ho MC, Wang YC, Tseng ST, et al. Hepatitis B Virus DNA Integration Drives Carcinogenesis and Provides a New Biomarker for HBV-related HCC. Cell Mol Gastroenterol Hepatol. 2023; 15: 921-9.

[338] Zoulim F, Chen P, Dandri M, Kennedy PT, Seeger C. Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome. J Hepatol. 2024; 81: 1087-99.

[339] Zhu C, Zhang C, Wang S, Xun Z, Zhang D, Lan Z, et al. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. J Immunother Cancer. 2024; 12:e008686.

[340] Yoo C, Jeong H, Jeong JH, Kim KP, Lee S, Ryoo B, et al. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. J Hepatol. 2025; 82: 861-70.

[341] Muraki R, Morita Y, Ida S, Kitajima R, Furuhashi S, Takeda M, et al. Phosphatidylcholine in bile-derived small extracellular vesicles as a novel biomarker of cholangiocarcinoma. Cancer Med. 2023; 12: 13007-18.

[342] Wen N, Peng D, Xiong X, Liu G, Nie G, Wang Y, et al. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring. Signal Transduct Target Ther. 2024; 9: 107.

[343] Zhu X, Trehan R, Xie C. Primary liver cancer organoids and their application to research and therapy. J Natl Cancer Cent. 2024; 4: 195-202.

[344] Pastore M, Giachi A, Spínola-Lasso E, Marra F, Raggi C. Organoids and spheroids: advanced in vitro models for liver cancer research. Front Cell Dev Biol. 2025; 12: 1536854.

[345] Habibollahi P, Gurevich A, Hui JZ, Weinfurtner K, McClung G, Adler J, et al. Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma. Mol Cancer Ther. 2024; 23: 1815-26.

[346] Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med. 2024; 30: 1044-53.

[347] Rezaee-Zavareh MS, Kim N, Yeo YH, Kim H, Lee JM, Sirlin CB, et al. Artificial intelligence in liver cancer research: a scientometrics analysis of trends and topics. Front Oncol. 2024; 14: 1355454.

[348] Wang L, Fatemi M, Alizad A. Artificial intelligence techniques in liver cancer. Front Oncol. 2024; 14: 1415859.

[349] Chaiteerakij R, Ariyaskul D, Kulkraisri K, Apiparakoon T, Sukcharoen S, Chaichuen O, et al. Artificial intelligence for ultrasonographic detection and diagnosis of hepatocellular carcinoma and cholangiocarcinoma. Sci Rep. 2024; 14: 20617.

[350] Seven İ, Bayram D, Arslan H, Köş FT, Gümüşlü K, Aktürk Esen S, et al. Predicting hepatocellular carcinoma survival with artificial intelligence. Sci Rep. 2025; 15: 6226.

[351] Chierici A, Lareyre F, Iannelli A, Salucki B, Goffart S, Guzzi L, et al. Applications of artificial intelligence in liver cancer: A scoping review. Artif Intell Med. 2025; 169: 103244.

[352] Huang J, Bai X, Qiu Y, He X. Application of AI on cholangiocarcinoma. Front Oncol. 2024; 14: 1324222.

[353] Wang KX, Li YT, Yang SH, Li F. Research trends and hotspots evolution of artificial intelligence for cholangiocarcinoma over the past 10 years: a bibliometric analysis. Front Oncol. 2025; 14: 1454411.

[354] Zerunian M, Polidori T, Palmeri F, Nardacci S, Del Gaudio A, Masci B, et al. Artificial Intelligence and Radiomics in Cholangiocarcinoma: A Comprehensive Review. Diagnostics (Basel). 2025; 15: 148.

[355] Mödl B, Moritsch S, Zwolanek D, Eferl R. Type I and II interferon signaling in colorectal cancer liver metastasis. Cytokine. 2023; 161: 156075.

[356] Marliot F, Chen X, Kirilovsky A, Sbarrato T, El Sissy C, Batista L, et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J Immunother Cancer. 2020; 8: e000272.

[357] Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, et al. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. J Natl Cancer Inst. 2018; 110: 438.

[358] Oliveira MF, Romero JP, Chung M, Williams SR, Gottscho AD, Gupta A, et al. High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer. Nat Genet. 2025; 57: 1512-23.

[359] Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350-6.

[360] Mzoughi S, Schwarz M, Wang X, Demircioglu D, Ulukaya G, Mohammed K, et al. Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Nat Genet. 2025; 57: 402-12.

[361] Cammareri P, Raponi M, Hong Y, Billard CV, Peckett N, Zhu Y, et al. Loss of colonic fidelity enables multilineage plasticity and metastasis. Nature. 2025; 644: 547-56.

[362] Moorman A, Benitez EK, Cambulli F, Jiang Q, Mahmoud A, Lumish M, et al. Progressive plasticity during colorectal cancer metastasis. Nature. 2025; 637: 947-54.

[363] Yu J, Liang Y, Zhang Q, Ding H, Xie M, Zhang J, et al. An interplay between human genetics and intratumoral microbiota in the progression of colorectal cancer. Cell Host Microbe. 2025; 33: 657-70.e6.

[364] Zepeda-Rivera M, Minot SS, Bouzek H, Wu H, Blanco-Míguez A, Manghi P, et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature. 2024; 628: 424-32.

[365] Fellows RC, Chun SK, Larson N, Fortin BM, Mahieu AL, Song WA, et al. Disruption of the intestinal clock drives dysbiosis and impaired barrier function in colorectal cancer. Sci Adv. 2024; 10:eado1458.

[366] Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009; 459: 262-5.

[367] Yoon H, Lee S. Integration of Genomic Profiling and Organoid Development in Precision Oncology. Int J Mol Sci. 2021; 23: 216.

[368] Polak R, Zhang ET, Kuo CJ. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat Rev Cancer. 2024; 24: 523-39.

[369] Yi K, Park SH, Kim DU, Jeon DY, Lee HJ, Song GA, et al. Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer. In Vivo. 2023; 37: 1751-9.

[370] Toshimitsu K, Takano A, Fujii M, Togasaki K, Matano M, Takahashi S, et al. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. Nat Chem Biol. 2022; 18: 605-14.

[371] Li H, Liu H, Chen K. Living biobank-based cancer organoids: prospects and challenges in cancer research. Cancer Biol Med. 2022; 19: 965-82.

[372] Qi GX, Zhao RX, Gao C, Ma ZY, Wang S, Xu J. Recent advances and challenges in colorectal cancer: From molecular research to treatment. World J Gastroenterol. 2025; 31: 106964.

[373] Hildebrand LA, Pierce CJ, Dennis M, Paracha M, Maoz A. Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer. Cancers (Basel). 2021; 13: 391.

[374] Lee SH, Jang HJ. Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology. Clin Mol Hepatol. 2022; 28: 754-72.

[375] Ruusuvuori P, Valkonen M, Latonen L. Deep learning transforms colorectal cancer biomarker prediction from histopathology images. Cancer Cell. 2023; 41: 1543-5.

[376] Sirinukunwattana K, Domingo E, Richman SD, Redmond KL, Blake A, Verrill C, et al. Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut. 2021; 70: 544-54.

[377] Foersch S, Glasner C, Woerl AC, Eckstein M, Wagner DC, Schulz S, et al. Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nat Med. 2023; 29: 430-9.

[378] Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019; 25: 1054-6.

[379] Oh JM, Kim S, Tsung C, Kent E, Jain A, Ruff SM, et al. Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type. Front Immunol. 2025; 16: 1571731.

[380] Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022; 40: 161-70.

[381] Tan PB, Verschoor YL, van den Berg JG, Balduzzi S, Kok NFM, Ijsselsteijn ME, et al. Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers. Nature. 2025; 648: 726-35.

[382] Gallois C, Bergen ES, Auclin É, Pernot S, Higué J, Trouilloud I, et al. Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study. ESMO Open. 2024; 9: 103696.

[383] Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019; 381: 1632-43.

[384] Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, et al. Combined PD-1, BRAF and MEK inhibition in BRAF^V600E colorectal cancer: a phase 2 trial. Nat Med. 2023; 29: 458-66.

[385] Zhao Y, Feng X, Chen Y, Selfridge JE, Gorityala S, Du Z, et al. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers. Cancer Res. 2020; 80: 4815-27.

[386] Centonze A, Roura A, Novillo-Font M, Giordano C, Hernando-Momblona X, Llanses M, et al. A plastic EMP1⁺ to LGR5⁺ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer. Cancer Discov. 2025;[Epub ahead of print].

[387] Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Martínez-Martín S, Foradada L, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024; 30: 762-71.

[388] Bailey C, Pich O, Thol K, Watkins TBK, Luebeck J, Rowan A, et al. Origins and impact of extrachromosomal DNA. Nature. 2024; 635: 193-200.

[389] Tang J, Weiser NE, Wang G, Chowdhry S, Curtis EJ, Zhao Y, et al. Enhancing transcription-replication conflict targets ecDNA-positive cancers. Nature. 2024; 635: 210-8.

[390] Russo M, Pompei S, Sogari A, Corigliano M, Crisafulli G, Puliafito A, et al. A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. Nat Genet. 2022; 54: 976-84.

[391] Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin XL, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023; 31: 781-97.e9.

[392] Lui RN, Tsoi KKF, Ho JMW, Lo CM, Chan FCH, Kyaw MH, et al. Global Increasing Incidence of Young-Onset Colorectal Cancer Across 5 Continents: A Joinpoint Regression Analysis of 1,922,167 Cases. Cancer Epidemiol Biomarkers Prev. 2019; 28: 1275-82.

[393] Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, et al. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019; 125: 2002-10.

[394] Burnett-Hartman AN, Murphy CC, Lee JK. Novel, Emerging Risk Factors for Colorectal Cancer Remain Understudied. Gastroenterology. 2022; 163: 574-6.

[395] Díaz-Gay M, Dos Santos W, Moody S, Kazachkova M, Abbasi A, Steele CD, et al. Geographic and age variations in mutational processes in colorectal cancer. Nature. 2025; 643: 230-40.

[396] Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010; 10: 40.

[397] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55: 245-64.

[398] Cadranel JF, Nousbaum JB. Ponction biopsie hépatique (PBH): réalisation pratique et indications. Post-U. 2002; 144: 152.

[399] Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med. 2000; 133: 665-75.

[400] van der Poorten D, Kwok A, Lam T, Ridley L, Jones DB, Ngu MC, et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J. 2006; 36: 692-9.

[401] Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 1997; 113: 1609-16.

[402] Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998; 5: 187-92.

[403] Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations [Internet]. UpToDate; c2026 [cited 2023 Aug 14]. Available from: https://www.uptodate.com/contents/noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-tests-and-imaging-examinations

[404] Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003; 163: 218-24.

[405] Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001; 96: 3142-6.

[406] Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, Adams P. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology. 2002; 36: 673-8.

[407] Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004; 99: 1160-74.

[408] Guéchot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol. 1994; 20: 388-93.

[409] Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013; 57: 103-11.

[410] Kimura S, Tamaki N, Higuchi M, Shima T, Taguchi M, Yamazaki Y, et al. Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds. J Clin Med. 2025; 14: 8473.

[411] McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59: 1265-9.

[412] Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017; 66: 1486-501.

[413] Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T ; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357: 1069-75.

[414] Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128: 343-50.

[415] Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet M, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005; 42: 1373-81.

[416] Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol. 2006; 101: 547-55.

[417] Sporea I, Sirli R, Bota S, Fierbinţeanu-Braticevici C, Petrişor A, Badea R, et al. Is ARFI elastography reliable for predicting fibrosis severity in chronic HCV hepatitis? World J Radiol. 2011; 3: 188-93.

[418] Hu X, Qiu L, Liu D, Qian L. Acoustic Radiation Force Impulse (ARFI) Elastography for non-invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med Ultrason. 2017; 19: 23-31.

[419] Nierhoff J, Chávez Ortiz AA, Herrmann E, Zeuzem S, Friedrich-Rust M. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol. 2013; 23: 3040-53.

[420] Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010; 256: 640-7.

[421] Jiang T, Tian G, Zhao Q, Kong D, Cheng C, Zhong L, et al. Diagnostic Accuracy of 2D-Shear Wave Elastography for Liver Fibrosis Severity: A Meta-Analysis. PLoS One. 2016; 11: e0157219.

[422] Li Y, Huang YS, Wang ZZ, Yang ZR, Sun F, Zhan SY, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2016; 43: 458-69.

[423] Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011; 54: 650-9.

[424] Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008; 134: 960-74.

[425] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388-402.

[426] Ichikawa S, Motosugi U, Ichikawa T, Sano K, Morisaka H, Enomoto N, et al. Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci. 2012; 11: 291-7.

[427] Hennedige TP, Wang G, Leung FP, Alsaif HS, Teo LL, Lim SG, et al. Magnetic Resonance Elastography and Diffusion Weighted Imaging in the Evaluation of Hepatic Fibrosis in Chronic Hepatitis B. Gut Liver. 2017; 11: 401-8.

[428] Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011; 259: 749-56.

[429] Makar J, Abdelmalak J, Con D, Hafeez B, Garg M. Use of artificial intelligence improves colonoscopy performance in adenoma detection: a systematic review and meta-analysis. Gastrointest Endosc. 2025; 101: 68-81.e8.

[430] Liguori A, Zoncapè M, Casazza G, Easterbrook P, Tsochatzis EA. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025; 10: 332-49.

[431] Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023; 79: 516-37.

[432] World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310: 2191-4.

[433] Council for International Organizations of Medical Sciences (CIOMS); World Health Organization (WHO). International Ethical Guidelines for Health-related Research Involving Humans: Prepared by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). 4th ed. Geneva: Council for International Organizations of Medical Sciences; 2016.

[434] Mendelson D. The European Union General Data Protection Regulation (EU 2016/679) and the Australian My Health Record Scheme - A Comparative Study of Consent to Data Processing Provisions. J Law Med. 2018; 26: 23-38.

[435] Your Rights Under HIPAA [Internet]. U.S. Department of Health & Human Services; [cited 2025 Sep 21. Available from: https://www.hhs.gov/hipaa/for-individuals/guidance-materials-for-consumers/index.html

[436] Budzyń K, Romańczyk M, Kitala D, Kołodziej P, Bugajski M, Adami HO, et al. Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy: a multicentre, observational study. Lancet Gastroenterol Hepatol. 2025; 10: 896-903.

[437] Ahmad OF. Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy? Lancet Gastroenterol Hepatol. 2025; 10: 872-3.

[438] Gomaa A, Gomaa M, Allam N, Waked I. Hepatitis C Elimination in Egypt: Story of Success. Pathogens. 2024; 13: 681.

[439] Chun HS, Lee M. Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis”. Clin Mol Hepatol. 2025; 31: 261-3.

[440] Kim NJ, Vutien P, Cleveland E, Cravero A, Ioannou GN. Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023; 21: 1723-38.e5.

[441] Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017; 67: 1204-12.

[442] Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol. 2023; 78: 534-42.

[443] Liu SJ, Zhang X, Yan LJ, Wang HC, Ding ZN, Liu H, et al. Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis. J Cancer Res Clin Oncol. 2025; 151: 77.

[444] Peng J, Wang L, Wang Q, Li H, Lin L, He J. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis. Front Pharmacol. 2024; 15: 1393861.

[445] Singh ME, James SP, Germino GG, Rodgers GP. Achieving Health Equity Through Digestive Diseases Research and Scientific Workforce Diversity. Gastroenterology. 2022; 162: 1597-601.e1.

[446] Mercado CI, Bullard KM, Bolduc MLF, Andrews CA, Freggens ZRF, Liggett G, et al. A Shift in Approach to Addressing Public Health Inequities and the Effect of Societal Structural and Systemic Drivers on Social Determinants of Health. Public Health Rep. 2024;[Epub ahead of print].

[447] Sarikhani Y, Kalavani A, Najibi SM. Scientific Mapping of Global Research on Health Equity by 2023: A Bibliometric Study. Health Sci Rep. 2025; 8: e70478.